Marcus Skribek

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

För detaljerad information, se den engelska presentationssidan.

Artiklar

Journal article: ANNALS OF ONCOLOGY. 2024;35:s858
1361P The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Koulouris AV; Skribek MC; Kamali C; Grundberg O; Lampa E; Gubanski M; Hydbring P; Ekman S; Tsakonas G
Article: EUROPEAN JOURNAL OF RADIOLOGY. 2024;177:111557
Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar)
Grundberg O; Skribek M; Swerkersson S; Skorpil M; Kolbeck K; Grozman V; Nyren S; Tsakonas G
Article: ACTA ONCOLOGICA. 2023;62(12):1808-1814
Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals
Skribek M; Brunnstrom H; Oskarsdottir G; Grive MP; Aricak O; Planck M; Jatta K; Naserhojati H; de Flon FH; Ekman S
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s638
EP11.03-40 An Observational Study to Identify Selection Criteria for Initiation of Different First Line Treatment Options in NSCLC Patients
Skribek M; Sierakowiak A; Koulouris A; Rounis K; Goenechea J; Labor M; Lund HW; Axelsson I; Fornwall A; Tsakonas G; Koyi H
Article: LUNG CANCER. 2022;166:132-134
Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report
Skribek M; Bozoky B; Tsakonas G
Article: CANCERS. 2021;13(7):1562
Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
Rounis K; Skribek M; Makrakis D; De Petris L; Agelaki S; Ekman S; Tsakonas G
Article: EUROPEAN JOURNAL OF CANCER. 2021;145:245-254
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Article: CANCERS. 2020;12(12):E3707-3707
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting
Skribek M; Rounis K; Makrakis D; Agelaki S; Mavroudis D; De Petris L; Ekman S; Tsakonas G

Alla övriga publikationer

Thesis / dissertation: KAROLINSKA INSTITUTET. 2024
Strategies for optimizing immune checkpoint inhibition in advanced non-small cell lung cancer
Skribek M
Thesis / dissertation: 2024
Strategies for optimizing immune checkpoint inhibition in advanced non-small cell lung cancer
Skribek M
Thesis / dissertation: KAROLINSKA INSTITUTET. 2024
Strategies for optimizing immune checkpoint inhibition in advanced non-small cell lung cancer
Skribek M
Preprint: MEDRXIV. 2024
The Brain-Lung Immunotherapy Prognostic (BLIP) Score: A Novel Robust Tool for Prognostication in Non-Small Cell Lung Cancer Patients with Brain Metastases
Skribek M; Livanou M-E; Vathiotis I; Strandman V; Thorell A; Koulouris A; Syrigos K; Ekman S; Tsakonas G
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s599
EP09.04-01 Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases
Tsakonas G; Skribek M; Kamali C; Zerdes I; Jóhannsdóttir B; Ekman S
Review: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023;11(3):e005841
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature
Liu LL; Skribek M; Harmenberg U; Gerling M
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):S638
An Observational Study to Identify Selection Criteria for Initiation of Different First Line Treatment Options in NSCLC Patients
Skribek M; Sierakowiak A; Koulouris A; Rounis K; Goenechea J; Labor M; Lund HW; Axelsson I; Fornwall A; Tsakonas G; Koyi H
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):S599
Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases
Tsakonas G; Skribek M; Kamali C; Zerdes I; Johannsdottir B; Ekman S
Conference publication: ANNALS OF ONCOLOGY. 2022;33(7):S1087
Real-world insights into non-small cell lung cancer patients with MET exon 14 skipping mutations: A Swedish retrospective study from two university hospitals
Skribek M; Brunnstrom H; Aricak O; Planck M; Jatta K; Oskarsdottir GN; Naserhojati H; Haglund F; Ekman S
Preprint: MEDRXIV. 2022
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Systematic review of the literature
Liu LL; Skribek M; Harmenberg U; Gerling M
Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):732-754
Complications following novel therapies for non-small cell lung cancer
Skribek M; Rounis K; Tsakonas G; Ekman S

Forskningsbidrag

Research Grant
Radiumhemmets Forskningsfonder
1 June 2022 - 31 May 2024

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2023-2026

Gästforskning och resestipendier

Clinical Research Fellow, Memorial Sloan Kettering Cancer Center, - Joined MSKCC to deepen expertise in oncology through firsthand learning of cancer management and treatment practices. - Collaborated with multidisciplinary teams to enhance patient outcomes and advance cancer care methodologies. - Specialized in radiotheranostics at the Jason Lewis Lab, integrating diagnostic imaging and targeted therapy to develop precision medicine approaches. - Involved in research focusing on DLL3 in small cell lung cancer and DLK1 in sarcoma, aiming to develop effective therapies for aggressive cancer types. - Worked under the supervision of industry-leading experts to pioneer novel cancer therapy methods., 2024-2024

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Gästforskning och resestipendier

Nyheter från KI

Kalenderhändelser från KI